Key Takeaways AMGN is expected to beat Q2 estimates, with the consensus for EPS pegged at $5.25 and for revenues at$8.86B.Volume growth of Evenity, Repatha and Blincyto is likely to have driven top-line gains despite price declines.New launches like Bekemv and Pavblu may boost revenues, but biosimilar and pricing pressure remain key risks.We expect Amgen (AMGN) to beat expectations when it reports second-quarter 2025 results on Aug. 5 after market close. In the last reported quarter, the company beat earni ...